Synthetic peptides mimicking lipopolysaccharide as a potential vaccine candidates against Vibrio cholerae serogroup O1
AbstractBackground and Objectives: Cholera is a life-threatening diarrhea caused mainly by Gram-negative marine habitant Vibrio cholerae serogroup O1. Cholera vaccination is limited mainly to developed countries, due to the cumbersome and expensive task of vaccine production. In the present work, the aim was to study the immunogenicity of the synthetic mimotopes through two different routes of injection and oral administration. Lipopolysaccharide (LPS) is one of the immunogenic components in Gram-negative bacteria, which cannot be used as a vaccine candidate, due to its high toxic effect.Materials and Methods: Three phage-displayed selected peptides, with high affinity to anti-LPS VHH tested in our previous study, were chemically synthesized and used as a potential vaccine candidate. In order to enhance the antigenic properties and safe delivery, these peptides were conjugated to BSA as a carrier and encapsulated with PLGA. Peptides were injected intra-peritoneally or administered orally, alone or in combined form. Mice sera and feces were collected for assessment of humoral and mucosal antibody titers, respectively. ELISA plates were coated with mimotope conjugates and V. cholerae, Shigella sonnei and ETEC were used as target antigens. Antibody titer was measured by adding IgG and IgA as primary antibodies.Results: Mice receiving three selected synthetic peptide conjugates (individually or in combination) showed higher antibody titer compared to control groups. The mice immunized with synthetic peptides were protected against more than 15 LD50 of V. cholerae. Conclusion: These peptides are mimicking LPS and can potentially act as vaccine candidates against V. cholerae.
Siddique A, Nair G, Alam M, Sack D, Huq A, Nizam A, et al. El Tor cholera with severe disease: a new threat to Asia and beyond. Epidemiol Infect 2010; 138:347-352.
WHO Global Report. World Health Organization. Weekly Epidemiological Record 2012. WHO/WER/2012.87.
Ebrahimizadeh W, Gargari SM, Rajabibazl M, Ardekani LS, Zare H, Bakherad H. Isolation and characterization of protective anti-LPS nanobody against V. cholerae O1 recognizing Inaba and Ogawa serotypes. Appl Microbiol Biotechnol 2013; 97:4457-4466.
Igbinosa EO, Okoh AI. Toxigenic Vibrio cholerae strains and their associated malaises. Afr J Microbiol Res 2009; 3:200-211.
Faruque SM, Sack DA, Sack RB, Colwell RR, Takeda Y, Nair GB. Emergence and evolution of Vibrio cholerae O139. Proc Natl Acad Sci 2003; 100:1304-1309.
Kristian SA, Hwang JH, Hall B, Leire E, Iacomini J, Old R, et al. Retargeting pre-existing human antibodies to a bacterial pathogen with an alpha-Gal conjugated aptamer. J Mol Med 2015; 93:619-631.
Grandi G. Antibacterial vaccine design using genomics and proteomics. Trends Biotechnol 2001; 19:181-188.
Meloen R, Puijk W, Slootstra J. Mimotopes: realization of an unlikely concept. J Mol Recognit 2000; 13:352-359.
Muller C. Antigenic and immunogenic phage displayed mimotopes as substitute antigens applications and limitations. Comb Chem High Throughput Screen 2001; 4:75-110.
Parmley SF, Smith GP. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene 1988; 73:305-3018.
Monzavi-Karbassi B, Cunto-Amesty G, Luo P, Shamloo S, Blaszcyk-Thurin M, Kieber-Emmons T. Immunization with a carbohydrate mimicking peptide augments tumor-specific cellular responses. Int Immunol 2001; 13:1361-1365.
Tzianabos AO, Finberg RW, Wang Y, Chan M, Onderdonk AB, Jennings HJ, et al. T cells activated by zwitterionic molecules prevent abscesses induced by pathogenic bacteria. J Biol Chem 2000; 275:6733-6740.
Mohammad Pour Ghazi F, Mousavi Gargari SL. Development of lipopolysaccharide-mimicking peptides and their immunoprotectivity against Vibrio cholerae serogroup O1. J Pept Sci 2016; 22:682-688.
Sawasvirojwong S, Srimanote P, Chatsudthipong V, Muanprasat C. An adult mouse model of Vibrio cholerae-induced diarrhea for studying pathogenesis and potential therapy of cholera. PLoS Negl Trop Dis 2013; 7:e2293.
Geier MR, Trigg ME, Merril CR. Fate of bacteriophage lambda in non-immune germ-free mice. Nature 1973; 246:221-223.
Biswas B, Adhya S, Washart P, Paul B, Trostel AN, Powell B, et al. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun 2002; 70:204-210.
Townsend A, Bodmer H. Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 1989; 7:601-624.
Yewdell JW, Bennink JR. Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes. Adv Immunol 1992; 52:1-123.
Hoffmann P, Loleit M, Mittenbühler K, Beck W, Wiesmüller K-H, Jung G, et al. Induction of an epitope-specific humoral immune response by lipopeptide-hapten conjugates: enhancement of the anti-melittin response by a synthetic T helper (Th)-cell epitope. FEMS Immunol Med Microbiol 1997; 17:225-234.
Rammensee H-G, Bachmann J, Emmerich NPN, Bachor OA, Stevanović S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50:213-219.
Phalipon A, Folgori A, Arondel J, Sgaramella G, Fortugno P, Cortese R, et al. Induction of anti-carbohydrate antibodies by phage library-selected peptide mimics. Eur J Immunol 1997; 27:2620-2625.
Zhang X, Sun M, Zheng A, Cao D, Bi Y, Sun J. Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration. Eur J Pharm Sci 2012; 45:632-638.
Asadi-Ghalehni M, Ghaemmaghami M, Klimka A, Javanmardi M, Navari M, Rasaee MJ. Cancer immunotherapy by a recombinant phage vaccine displaying EGFR mimotope: an in vivo study. Immunopharmacol Immunotoxicol 2015; 37:274-279.